President of the National Cancer Institute of Canada G‐U Group, the Canadian Urologic Oncology Group and GU Global ▪ Member of ten editorial boards and serves as a reviewer for more than 30 urology and oncology journals. Published over 300 scientific articles and book chapters and has collaborated on over 800 scientific abstracts presented at scientific meetings around the world. ▪ Co‐editor of several books, including the first two editions of Understanding Prostate Cancer, which sold over 150,000 copies. ▪ Main research interests include molecular prognostic markers in prostate cancer and new treatments for advanced prostate cancer. He is currently coordinating more than 40 clinical and basic research projects in urologic oncology.

Prof. Fred Saad has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA/Novartis, Abbvie, Astellas, AstraZeneca, Amgen, Bayer, Janssen, Merck, Myovant, Pfizer, Sonofi and Tolmar.